台灣腸胃道基質瘤之存活率分析

腸胃道基質瘤是腸胃道疾病中常見的間葉細胞瘤，好發於50歲以上成人。本研究擬探討台灣腸胃道基質瘤病患之存活率。我們使用台灣健保資料庫篩選2004至2011年間診斷為腸胃道基質瘤之病患;以雲端技術、非關聯式資料庫MongoDB與JavaScript運算資料;以統計軟體R進行存活分析。我們依性別、年齡與標靶藥物(基利克與舒癌特)治療方式將病患分組並推估存活率。研究結果發現共7,357¬ 位病患罹患腸胃道基質瘤 (男性4,179人、平均64.30歲;女性3,178人、平均61.21歲)。女性的存活率優於男性 (p < .05)。兩種標靶藥物對延長病患存活時間有相同的效果 (p > .05)。

關鍵字

腸胃道基質瘤；存活分析；非關聯式資料庫； MongoDB ；基利克；舒癌特

並列摘要

Gastrointestinal Stromal Tumor (GIST) is a common mesenchymal tumor of gastrointestinal tract and occurs in patients aged over 50 years. This research analyzed GIST patient survival rates following target therapies. We used Taiwan National Health Insurance Research Database to identify GIST cases in 2004. These GIST patients were followed up until 2011. We used JavaScript, MongoDB, and cloud-based server to manage data and statistic R to analyze survivals. We compared GIST patients’ survivals by gender, age, and therapy therapies -- Glivec and Sutent. Results showed that a total of 7,357 GIST patients (4,179 males, mean age: 64.30 years; 3,178 females, mean age 61.21 years) were enrolled in the study. Female GIST patients had better survival rates (p < .05). The target therapies had same effects in lengthening GIST patients’ life span (p > .05).

並列關鍵字

Gastrointestinal Stromal Tumor (GIST) ； Survival Analysis ； non-relational database ； MongoDB ； Glivec (Imatinib) ； Sutent (Sunitinib)

參考文獻

Acin-Gandara D, Pereira-Perez F, Castano-Pascual A, Duran-Poveda M, Antequera-Perez A, Miliani-Molina C. (2012). Gastrointestinal stromal tumors: diagnosis and treatment. Cir Cir, 80(1), 8.

Google Scholar

Arne, G., Kristiansson, E., Nerman, O., Kindblom, L. G., Ahlman, H., Nilsson, B., & Nilsson, O. (2011). Expression profiling of GIST: CD133 is associated with KIT exon 11 mutations, gastric location and poor prognosis. Int J Cancer, 129(5), 1149-1161. doi: 10.1002/ijc.25755

Google Scholar

Blay, J. Y. (2009). New paradigms in gastrointestinal stromal tumour management. Ann Oncol, 20 Suppl 1, i18-24. doi: 10.1093/annonc/mdp075

Google Scholar

Blay, J. Y., von Mehren, M., & Blackstein, M. E. (2010). Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors. Cancer, 116(22), 5126-5137. doi: 10.1002/cncr.25267

Google Scholar

Chen, Y. Y., Yeh, C. N., Cheng, C. T., Chen, T. W., Rau, K. M., Jan, Y. Y., & Chen, M. F. (2011). Sunitinib for Taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance. World J Gastroenterol, 17(16), 2113-2119. doi: 10.3748/wjg.v17.i16.2113

Google Scholar

延伸閱讀

孫麗珠（2008）。台灣地區大腸直腸癌病患存活率之分析〔碩士論文，高雄醫學大學〕。華藝線上圖書館。https://doi.org/10.6832/KMU.2008.00019
陳吉芳（2007）。台灣人族群結腸直腸癌藥物基因體學研究〔碩士論文，中原大學〕。華藝線上圖書館。https://doi.org/10.6840/cycu200700561
Wu, F. T., Tsai, T. Y., Hsu, C. F., Pan, T. M., Chen, H. Y., & Su, I. J. (2005). 臺灣第一例腸出血性大腸桿菌感染症之分離與鏗定研究. Journal of the Formosan Medical Association, 104(3), 206-209. https://doi.org/10.29828/JFMA.200503.0012
羅傑明（2021）。以流行病學分析台灣大腸直腸癌之發生率〔碩士論文，國立暨南國際大學〕。華藝線上圖書館。https://doi.org/10.6837/ncnu202100188
Wang, T. H., Sung, J. L., Yu, J. Y., Wei, T. C., How, S. W., Wang, C. Y., Chen, D. S., Hsieh, S. C., Yang, T. H., Chen, K. M., Hsu, S. C., Lai, M. Y., Sheu, J. C., Lin, J. T., Yang, P. M., & Wu, C. F. (1984). Early Gastric Cancer in National Taiwan University Hospital: An Analysis of 106 Cases. 中華民國消化系醫學會雜誌, 1(1), 26-37. https://doi.org/10.6557/GJTa.198401_1(1).0005

國際替代計量

台灣腸胃道基質瘤之存活率分析

全文下載

主題瀏覽